Not FDA cleared.
Not available in the United States.
HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device is a new resting 12-lead electrocardiograph that uses continuous wavelet transform (CWT) signal processing to extract additional frequency information from the acquired ECG signal. This new information is a key aspect of the MyoVista wavECG AI-based algorithm that is designed to detect left ventricular (LV) relaxation abnormalities which are typically the earliest manifestation of left ventricular diastolic dysfunction (LVDD).. Extensive research confirms that almost all forms and co-morbidities of heart disease are associated with LVDD including hypertension, diabetes, valvular disease, ischemia, and reduced systolic function.
The MyoVista wavECG Device is an innovative advancement for electrocardiographic testing designed to provide physicians with new information to improve patient risk-assessment related to heart disease. This additional wavECG Information assists physicians in determining whether a patient should receive further testing, evaluation and/or treatment.